Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First EU Centralized Switch Goes To Alli, Could Spark More Applications

This article was originally published in The Pink Sheet Daily

Executive Summary

Central process will doubtless attract other switches, but countries will determine whether drug is still sold from pharmacies.

You may also be interested in...

GlaxoSmithKline Looks To Revamp U.S. Operations In Tough Environment

U.S. sales fell 13 percent in the third quarter due to generic competition and Avandia.

EU Shifts To Centralized OTC Process At Member States’ Expense – GSK Exec

Europe's development of a centralized process for approving nonprescription pharmaceuticals is sapping the resources of the regulatory agencies of European Union member states, a GlaxoSmithKline regulatory executive says

Behavioral Science Banner Maps The Future Of GSK Consumer Business

Roger Scarlett-Smith, the new head of GlaxoSmithKline's North American Consumer Healthcare business, believes a nonprescription statin is probably inevitable in the U.S., and his firm still wants to be in early on that opportunity

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts